Physicians' Academy for Cardiovascular Education

CV Risk Master Class - Asian chapter

May 10 -11, 2013, Kuala Lumpur

10' education - May 29, 2013

Educational Alliance to Optimize CV risk management
CV Risk Master Classes: Applying new insights to clinical practice

The lectures are recorded during the CardioVascular Risk Master Class, Asian chapter, held on May 10-11, 2013 in Kuala Lumpur, Malaysia. The presentations are intended for educational support of participants to the meeting. To view and open the presentations an additional log-on with a passcode is required. This passcode is provided to meeting participants only.


Click here to view the presentations


The challenge for CV Risk management in Asia:
What are the key opportunities?

Dato' Dr. Khoo Kah Lin, Kuala Lumpur, Malaysia



Call for action to prevent CV disease in Asia:
New strategies for early intervention

Prof John Deanfield, MD, UCL, London, United Kingdom



Macrovascular disease in diabetes;
Opportunities for lipid management

Prof. Karen Lam, MD, The University of Hong Kong, Hong Kong



Latest insights from clinical trials:

The unassailable case for LDL-c lowering & statin therapy

Kees Hovingh, MD, Academic Medical Centre, Amsterdam,The Netherlands



Blood pressure lowering and the prevention of CV disease and stroke

Prof. Peter Sever, MD, Imperial College London, United Kingdom



Novel therapies for the prevention of atherosclerotic vascular disease

John Kastelein, MD, Academic Medical Centre, Amsterdam, The Netherlands



The kidney & statin therapy: Friend or Foe?

Kees Hovingh, MDAcademic Medical Centre, Amsterdam,The Netherlands



Update on new CV Risk guidelines: an international perspective

Prof. John Deanfield, MDUCL, London, United Kingdom


Start video

The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: